N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide | 1197017-10-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide
• 英文别名: UCM924；N-(2-((3-Bromophenyl)(4-fluorophenyl)amino)ethyl)acetamide；N-[2-(N-(3-bromophenyl)-4-fluoroanilino)ethyl]acetamide
• CAS: 1197017-10-9
• 化学式: C₁₆H₁₆BrFN₂O
• 分子量: 351.218
• InChiKey: CDZDLQXUNHNNAQ-UHFFFAOYSA-N

物化性质

• 熔点：
  99-100 °C(Solv: ethyl ether (60-29-7); ligroine (8032-32-4))
• 沸点：
  529.6±45.0 °C(Predicted)
• 密度：
  1.405±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide 在 caesium carbonate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 21.67h， 生成 1-((acetyl(2-((3-bromophenyl)(4-fluorophenyl)amino)ethyl) carbamoyl)oxy)ethyl 2-((tert-butoxycarbonyl)amino)acetate
  参考文献：
  名称：

  [EN] NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF
  [FR] NOUVEAUX MODULATEURS DES RÉCEPTEURS DE LA MÉLATONINE, LEUR PROCÉDÉ DE PRODUCTION ET LEURS UTILISATIONS

  摘要：

  There is provided compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are melatonin MT2 agonists, as well as pharmaceutical compositions comprising such compounds. The invention also provides the use of the compounds and pharmaceutically acceptable salts thereof described herein (or pharmaceutical compositions comprising same) for managing or treating a disease, disorder or condition associated with melatonin receptor activity such as pain, neuropsychiatric disorders, sleep, chronobiological and circadian rhythm disorders, hyperthermia, and metabolic disorders. (I).

  公开号：

  WO2022213195A1
• 作为产物：
  描述：

  对氟碘苯 在 三乙基硅烷 、 palladium diacetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 12.5h， 生成 N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide
  参考文献：
  名称：

  [EN] NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF
  [FR] NOUVEAUX MODULATEURS DES RÉCEPTEURS DE LA MÉLATONINE, LEUR PROCÉDÉ DE PRODUCTION ET LEURS UTILISATIONS

  摘要：

  There is provided compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are melatonin MT2 agonists, as well as pharmaceutical compositions comprising such compounds. The invention also provides the use of the compounds and pharmaceutically acceptable salts thereof described herein (or pharmaceutical compositions comprising same) for managing or treating a disease, disorder or condition associated with melatonin receptor activity such as pain, neuropsychiatric disorders, sleep, chronobiological and circadian rhythm disorders, hyperthermia, and metabolic disorders. (I).

  公开号：

  WO2022213195A1

文献信息

• Direct, One-Pot Reductive Alkylation of Anilines with Functionalized Acetals Mediated by Triethylsilane and TFA. Straightforward Route for Unsymmetrically Substituted Ethylenediamine
  作者：Marika Righi、Annalida Bedini、Giovanni Piersanti、Federica Romagnoli、Gilberto Spadoni

  DOI：10.1021/jo102109f

  日期：2011.1.21

  A new, robust, and reliable method has been developed for the selective reductive N-alkylation of primary and secondary aromatic amines with some functionalized acetals using TFA/Et3SiH as a reagent combination. A variety of unsymmetrically substituted ethylenediamines can be synthesized in a one-pot procedure in excellent yields at room temperature. This new procedure offers significant advantages

  已开发出一种新的，稳健而可靠的方法，使用TFA / Et 3 SiH作为试剂组合，可以通过一些官能化的缩醛选择性地将伯和仲芳族胺进行N-烷基选择性还原。一锅法可以在室温下以优异的收率合成多种不对称取代的乙二胺。与以前的合成方法相比，该新方法具有明显的优势，包括简洁，温和的反应条件，优异的收率和较高的官能团耐受性。
• [EN] METHODS AND USES OF MELATONIN LIGANDS<br/>[FR] PROCÉDÉS ET UTILISATIONS DE LIGANDS DE TYPE MÉLATONINE
  申请人：GOBBI GABRIELLA

  公开号：WO2015021535A1

  公开（公告）日：2015-02-19

  The disclosure provides methods and uses for alleviating and/or treating pain including pain disorders using melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is 0, S or NR8; Y is chosen from hydrogen, aryl, heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, and R is chosen from hydrogen, hydroxyl, -OCF3, CF3, C1-C8 alkyl, C1-C8 alkyloxy, C1-C8 alkylthio, halogen and -Z-(CH2)P-A; R1 is chosen from C1-C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy- substituted C1-C4 alkyl, hydroxy-substituted C3-C6 cycloalkyl, and NHR5, wherein R5 is H, C1-C3 alkyl or C3-C6 cycloalkyl; R2 is chosen from hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R3 is chosen from hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl and halogen; R and R3 may be connected together to form an -0-(CH2)v bridge representing with the carbon atoms to which they are attached a 5- or 6-membered heterocyclic ring system; R4 is chosen from hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R6 is chosen from hydrogen and C1-C4 alkyl; R7 is chosen from hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl and halogen; and R8 is chosen from hydrogen and C1-C4 alkyl.

  本文提供了使用公式I中的褪黑素配体或其药学上可接受的盐来缓解和/或治疗疼痛，包括疼痛性疾病的方法和用途，其中：n为1或2；m为0、1或2；p为0、1、2、3、4、5、6、7或8；v为2或3；A为芳基或杂环芳基；Z为0、S或NR8；Y选自氢、芳基、杂环芳基、C1-C6烷基、C3-C6环烷基，R选自氢、羟基、-OCF3、CF3、C1-C8烷基、C1-C8烷氧基、C1-C8烷硫基、卤素和-Z-(CH2)P-A；R1选自C1-C4烷基、C3-C6环烷基、CF3、羟基取代的C1-C4烷基、羟基取代的C3-C6环烷基和NHR5，其中R5为H、C1-C3烷基或C3-C6环烷基；R2选自氢、C1-C4烷基、C1-C4烷氧基、OCF3、CF3、羟基和卤素；R3选自氢、C1-C4烷基、C1-C4烷氧基、OCF3、CF3、羟基和卤素；R和R3可以连接在一起形成一个-0-(CH2)v桥，代表它们附着的碳原子形成一个5-或6-成员杂环环系；R4选自氢、C1-C4烷基、C1-C4烷氧基、OCF3、CF3、羟基和卤素；R6选自氢和C1-C4烷基；R7选自氢、C1-C4烷基、C1-C4烷氧基、OCF3、CF3、羟基和卤素；R8选自氢和C1-C4烷基。
• Methods and Uses of Melatonin Ligands
  申请人：DOMINGUEZ LOPEZ Sergio

  公开号：US20160221932A1

  公开（公告）日：2016-08-04

  The disclosure provides methods and uses for alleviating and/or treating pain including pain disorders using melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is 0, S or NR 8 ; Y is chosen from hydrogen, aryl, heteroaryl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and R is chosen from hydrogen, hydroxyl, —OCF 3 , CF 3 , C 1 -C 8 alkyl, C 1 -C 8 alkyloxy, C 1 -C 8 alkylthio, halogen and —Z—(CH 2 p -A; R 1 is chosen from C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, CF 3 , hydroxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 3 -C 6 cycloalkyl, and NHR 5 , wherein R 5 is H, C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl; R 2 is chosen from hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl, and halogen; R 3 is chosen from hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl and halogen; R and R 3 may be connected together to form an -0-(CH 2 ) v bridge representing with the carbon atoms to which they are attached a 5- or 6-membered heterocyclic ring system; R 4 is chosen from hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl, and halogen; R 6 is chosen from hydrogen and C 1 -C 4 alkyl; R 7 is chosen from hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl and halogen; and R 8 is chosen from hydrogen and C 1 -C 4 alkyl.
• [EN] NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF<br/>[FR] NOUVEAUX MODULATEURS DES RÉCEPTEURS DE LA MÉLATONINE, LEUR PROCÉDÉ DE PRODUCTION ET LEURS UTILISATIONS
  申请人：[en]COSMAS THERAPEUTICS DEVELOPMENT INC.

  公开号：WO2022213195A1

  公开（公告）日：2022-10-13

  There is provided compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are melatonin MT2 agonists, as well as pharmaceutical compositions comprising such compounds. The invention also provides the use of the compounds and pharmaceutically acceptable salts thereof described herein (or pharmaceutical compositions comprising same) for managing or treating a disease, disorder or condition associated with melatonin receptor activity such as pain, neuropsychiatric disorders, sleep, chronobiological and circadian rhythm disorders, hyperthermia, and metabolic disorders. (I).